Puma Biotechnology, Inc.

As of July 7, 2025, Puma Biotechnology, Inc. is considered very attractive due to its undervalued status, evidenced by a low P/E ratio of 5, a Price to Book Value of 1.90, and an EV to EBITDA ratio of 3.15, despite recent short-term underperformance compared to the S&P 500.

As of June 10, 2025, Puma Biotechnology, Inc. is considered very attractive with a low P/E ratio of 5, a PEG ratio of 0.04 indicating strong growth potential, and a year-to-date return of 9.84%, outperforming the S&P 500, while its peers show less favorable valuations.

As of June 20, 2025, Puma Biotechnology, Inc. shows a mildly bullish trend, supported by bullish daily moving averages and a weekly MACD, despite mixed signals from the monthly indicators.

As of March 2022, the management team of Puma Biotechnology, Inc. includes Alan Auerbach (Chairman, President, and CEO), Jay Moyes (Lead Independent Director), Brian Stuglik, Ann Miller, Michael Miller, and Hugh O'Dowd (all Independent Directors). They oversee the company's strategic direction and operations.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing cancer treatments, with a market cap of $170.26 million and recent net sales of $46 million. Key financial metrics include a P/E ratio of 5.00 and a return on equity of 39.20%.

As of Jun 18, Puma Biotechnology, Inc. has a market capitalization of 170.26 million, with net sales of 232.71 million and net profit of 38.06 million over the latest four quarters. Shareholder's funds are 92.12 million, and total assets are 214.75 million as of Dec 24.